Business
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 American Diabetes Association (ADA) 85th Scientific Session being held June 20-23, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's
About this update from Genprex, Inc.
[{"type":"text","content":"Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 American Diabetes Association (ADA) 85th Scientific Session being held June 20-23, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.","length":607,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":106,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pdXst3fwi3qENRIKkbKHDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":106}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are thrilled that our collaborators have been selected to present positive preclinical data and new research on our novel gene therapy for diabetes at the largest worldwide scientific meeting for clinicians and researchers in diabetes," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are proud that our diabetes program has been recognized by an organization committed to the latest cutting-edge advances in diabetes. We are dedicated to advancing our diabetes program, and we believe GPX-002 has the potential to be a game-changer in emerging diabetes therapies."","length":613,"tagName":"p","attribs":{}},{"type":"text","content":"GPX-002 holds the potential for disease modification for long-term effectiveness, potentially replacing the daily burden of blood glucose monitoring and insulin replacement therapy. Genprex recently provide...